Sarepta Therapeutics Inc. announced that the company plans to temporarily pause all shipments of its gene therapy to treat Duchenne muscular dystrophy, Elevidys, in a reversal of its prior stance.
www.bloomberg.com
#Sarepta #Announces #Voluntary #Pause #Elevidys #Shipments
Sarepta Announces Voluntary Pause of Elevidys Shipments in US
